U.S. Markets Increased on Friday; Strategy Reached New Heights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Should l Buy ILMN?
Source: Barron's
U.S. Stock Market Performance: U.S. stock indexes experienced significant gains on Friday, with the overall market climbing by 2.47%.
Individual Index Gains: The S&P 500 index rose by 2.18%, while the Dow Jones Industrial Average saw an increase of 1.97%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to rise
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 123.670
Low
40.50
Averages
133.54
High
170.00
Current: 123.670
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina to Release Q1 2026 Earnings on April 30
- Earnings Release Schedule: Illumina will issue its Q1 2026 earnings report after market close on April 30, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Analyst Conference Call: On the same day, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss financial and operational results, aiming to bolster investor confidence.
- Live Webcast Access: Interested parties can access the live webcast via the Investor Info section of Illumina's website or through a direct link, ensuring timely connection by joining at least ten minutes before the scheduled start of the call.
- Replay Availability: A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days, further enhancing interaction and information sharing between the company and its investors.
See More
Illumina to Release Q1 2026 Financial Results
- Earnings Release Schedule: Illumina will issue its Q1 2026 financial results after market close on April 30, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: On the same day, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call at 1:30 PM Pacific Time to discuss financial and operational results, likely drawing considerable investor interest.
- Live Webcast Access: Interested parties can access the live webcast via the Investor Info section of Illumina's website, with a recommendation to join at least ten minutes early to ensure a timely connection.
- Replay Availability: A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days, allowing investors who could not attend live to catch up on the discussion.
See More
Illumina Board Changes and New Appointment
- Board Member Changes: Illumina announced that Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire at the upcoming annual shareholder meeting, marking a significant governance shift aimed at paving the way for future growth and innovation.
- New Director Nomination: The company has nominated David P. King to join the Board, who brings extensive experience in healthcare and life sciences, having previously served as Executive Chairman and CEO of Laboratory Corporation, expected to provide fresh perspectives and leadership to Illumina.
- Leadership and Innovation Synergy: King's appointment is viewed as a strategic move for Illumina to enhance the integration of genomics into medical practice, leveraging his experience in managing complex organizations and translating technological advances into real-world applications to drive the company's industry leadership.
- Board Support and Future Outlook: The strong support from Illumina's Board for King's nomination underscores the company's commitment to ongoing innovation and market leadership, which is anticipated to further enhance its competitive edge in the genomics sector.
See More
CNBC Launches Advocacy Platform for Rare Diseases
- Platform Launch: CNBC launched the CNBC Cures platform on January 8, aimed at giving a voice to the 30 million Americans living with rare diseases, connecting them with existing advocacy groups to drive attention and support from the medical community.
- Audience Engagement: The CNBC Cures newsletter has surpassed 20,000 subscribers, making it one of the fastest-growing newsletters on the network, indicating strong viewer interest and support for rare disease topics.
- Social Media Impact: Cures-related videos have garnered 1 million views across Facebook, TikTok, Instagram, and LinkedIn, demonstrating significant outreach and enhancing public awareness of rare diseases.
- Successful Summit: The inaugural CNBC Cures Summit attracted notable figures like Warren Buffett and sold out shortly after registration opened, with over 8,000 views for the livestream, reflecting heightened societal attention and support for rare disease issues.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration to advance precision oncology using next-generation sequencing (NGS) solutions, expected to promote equitable access to cancer biomarker testing and enhance patient convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic (IVD) tests, aiming to bridge gaps in precision oncology and drive advancements in personalized cancer care.
- Liquid and Tissue Biopsy Integration: The collaboration will explore co-commercializing Labcorp's FDA-authorized liquid biopsy PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, aiming to provide broader biomarker testing for hospitals and community health systems.
- Clinical Utility Research: In a joint study, Illumina's CGP detected variants in over 72% of more than 7,600 non-small cell lung cancer samples that had current targeted therapies or clinical trials, demonstrating CGP's effectiveness in identifying tumor genomic features.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Illumina to Release Q1 2026 Earnings on April 30
- Earnings Release Schedule: Illumina will issue its Q1 2026 earnings report after market close on April 30, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Analyst Conference Call: On the same day, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss financial and operational results, aiming to bolster investor confidence.
- Live Webcast Access: Interested parties can access the live webcast via the Investor Info section of Illumina's website or through a direct link, ensuring timely connection by joining at least ten minutes before the scheduled start of the call.
- Replay Availability: A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days, further enhancing interaction and information sharing between the company and its investors.
See More
Illumina to Release Q1 2026 Financial Results
- Earnings Release Schedule: Illumina will issue its Q1 2026 financial results after market close on April 30, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: On the same day, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call at 1:30 PM Pacific Time to discuss financial and operational results, likely drawing considerable investor interest.
- Live Webcast Access: Interested parties can access the live webcast via the Investor Info section of Illumina's website, with a recommendation to join at least ten minutes early to ensure a timely connection.
- Replay Availability: A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days, allowing investors who could not attend live to catch up on the discussion.
See More
Illumina Board Changes and New Appointment
- Board Member Changes: Illumina announced that Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire at the upcoming annual shareholder meeting, marking a significant governance shift aimed at paving the way for future growth and innovation.
- New Director Nomination: The company has nominated David P. King to join the Board, who brings extensive experience in healthcare and life sciences, having previously served as Executive Chairman and CEO of Laboratory Corporation, expected to provide fresh perspectives and leadership to Illumina.
- Leadership and Innovation Synergy: King's appointment is viewed as a strategic move for Illumina to enhance the integration of genomics into medical practice, leveraging his experience in managing complex organizations and translating technological advances into real-world applications to drive the company's industry leadership.
- Board Support and Future Outlook: The strong support from Illumina's Board for King's nomination underscores the company's commitment to ongoing innovation and market leadership, which is anticipated to further enhance its competitive edge in the genomics sector.
See More
CNBC Launches Advocacy Platform for Rare Diseases
- Platform Launch: CNBC launched the CNBC Cures platform on January 8, aimed at giving a voice to the 30 million Americans living with rare diseases, connecting them with existing advocacy groups to drive attention and support from the medical community.
- Audience Engagement: The CNBC Cures newsletter has surpassed 20,000 subscribers, making it one of the fastest-growing newsletters on the network, indicating strong viewer interest and support for rare disease topics.
- Social Media Impact: Cures-related videos have garnered 1 million views across Facebook, TikTok, Instagram, and LinkedIn, demonstrating significant outreach and enhancing public awareness of rare diseases.
- Successful Summit: The inaugural CNBC Cures Summit attracted notable figures like Warren Buffett and sold out shortly after registration opened, with over 8,000 views for the livestream, reflecting heightened societal attention and support for rare disease issues.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration to advance precision oncology using next-generation sequencing (NGS) solutions, expected to promote equitable access to cancer biomarker testing and enhance patient convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic (IVD) tests, aiming to bridge gaps in precision oncology and drive advancements in personalized cancer care.
- Liquid and Tissue Biopsy Integration: The collaboration will explore co-commercializing Labcorp's FDA-authorized liquid biopsy PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, aiming to provide broader biomarker testing for hospitals and community health systems.
- Clinical Utility Research: In a joint study, Illumina's CGP detected variants in over 72% of more than 7,600 non-small cell lung cancer samples that had current targeted therapies or clinical trials, demonstrating CGP's effectiveness in identifying tumor genomic features.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
